Ir a las Transacciones
Salud

CARSO Group has acquired Bactéries et Aliments

CARSO Group has strengthened its leadership in the food safety sector through the acquisition of Bactéries et Aliments.

Established in 1992 and headquartered in France, CARSO is one of the leading providers of analytical services in the French market, with operations in several neighboring countries. The company offers a broad range of analyses, including water and environmental testing, occupational hygiene and building health, food safety, genetic testing and pharmaceutical analysis. In 2021, ARCHIMED became CARSO’s majority shareholder, in partnership with CAPZA, Siparex, the management team and the company’s founders. Since then, ARCHIMED has supported CARSO’s organic and external growth across Europe through targeted acquisitions and strategic partnerships in high-potential market segments. The shared objective is to further strengthen CARSO’s position as an independent, entrepreneurial and international platform in the analytical services industry.

Founded over 20 years ago, Bactéries et Aliments is a laboratory specializing in microbiological analysis. It is recognized in the field of food hygiene for its customized services, expert guidance and cutting-edge R&D activities that support development projects within the food industry.

Oaklins’ team in France advised CARSO and its shareholders on the acquisition of Bactéries et Aliments.

Partes

Contáctese con el equipo de la transacción

Armelle Brossard Laborderie

Socio
Lyon, Francia
Oaklins France

Océane Chainho

Asociado Director
Paris, Francia
Oaklins France

Transacciones relacionadas

Medicija has acquired Saulės Šeimos Medicinos Centras
Salud

Medicija has acquired Saulės Šeimos Medicinos Centras

Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.

Aprenda más
Quimpharma has completed the divestiture of a product portfolio to Megalabs
Salud

Quimpharma has completed the divestiture of a product portfolio to Megalabs

Quimpharma has completed the divestiture of a product portfolio to Megalabs México.

Aprenda más
IXICO has completed a fundraising
Salud

IXICO has completed a fundraising

IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.

Aprenda más